Zoetis Inc
NYSE:ZTS
Zoetis Inc
NYSE:ZTS
Price:
174.21 USD
0.28%
Updated:
May 17, 2024
P/S
Price to Sales
Price to Sales
9.1
Current
10.2
Median
2.5
Industry
Lower
than median
Higher
than industry value
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
P/S
=9.1
Market Cap
/
79.4B
Revenue
8.7B
All Countries
| Market Cap | P/S | ||||
|---|---|---|---|---|---|
| US |
|
Zoetis Inc
NYSE:ZTS
|
79.4B USD | 9.1 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
734.8B USD | 20.5 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 16.5 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
371.4B USD | 4.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
330.7B USD | 5.4 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
187.4B GBP | 5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
188.8B CHF | 3.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.6B CHF | 3.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161.2B USD | 2.9 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/S
8.6
2-Years Forward
P/S
8
3-Years Forward
P/S
7.5
You don't have any saved screeners yet
